All sponsors

LaNova Medicines Limited

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS13
PHASE 3 / 2-31
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO50%

Delay Index: of 8 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.8 months). See all sponsors →

Open LaNova Medicines Limited on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
LM-24C5
NCT06187402
P1/2RecruitingAdvanced Solid Tumor492026-06-30 (+13 mo)
LM-108
NCT05518045
P1/2Active, not recruitingAdvanced Solid Tumor3922026-10-31 (+15 mo)
LM-299
NCT06650566
P1/2RecruitingMalignant Tumors1082026-12
LM101
NCT05615974
P1/2RecruitingMalignant Tumors1392027-01-11 (+25 mo)
LM-168
NCT06868199
P1/2RecruitingAdvanced Solid Tumours872027-08-01
LM-168
NCT07669415
P2RecruitingAdvanced Solid Tumor1082027-12-15
LM-108
NCT06873854
P2Not yet recruitingAdvanced Solid Tumor842028-01-26
LM-24C5
NCT07387081
P2RecruitingAdvanced Solid Tumor Cancer1302028-05-21
LM-350 for injection
NCT07112222
P1/2RecruitingMalignant Tumors802028-06-30
LM-108 in combination with Toripalimab
NCT07362186
P3RecruitingLocally Advanced or Metastatic GC and GCJ Adenocarcinoma4002028-08-17
LM-2417
NCT06682780
P1/2RecruitingAdvanced Solid Tumor3202028-12-25 (+13 mo)
LM-364 for injection
NCT07694765
P1/2Not yet recruitingMalignant Tumors902028-12-31
LM364
NCT07847905
P1/2Enrolling by invitationAdvanced Solid Tumor Cancer902030-10-19